Abstract: An antibody or antigen binding fragment thereof that binds to a Fn14, wherein the antibody or antigen binding fragment thereof is an antagonist and non-agonist of Fn14.

Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

Abstract: An antibody or antigen binding fragment thereof that binds to an IL-36, wherein the antibody or antigen binding fragment thereof binds to both IL-36? and IL-36?, and wherein the antibody is an antagonist of both IL-36? and IL-36?.

Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

Abstract: The present invention relates to a method and a medicament for airway and/or lung diseases such as moderate and/or severe asthma disease, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and systemic sclerosis. The medicament contains an agent which inhibits TL1A-DR3 interaction, and the method involves administering an effective amount of the agent to a subject to inhibit at least one symptom, feature or condition selected from hyperplasia of epithelial cells, epithelial metaplasia, hypertrophy of smooth muscle cells, and hyperproliferation of smooth muscle cells, production of extracellular matrix, and/or airway and/or lung tissue remodeling.

Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

Abstract: The invention relates to IL-1O Receptor alpha (IL-1OR?) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IOR?) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1OR?) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.

Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

Abstract: The invention relates to IL-1O Receptor alpha (IL-1OR?) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IOR?) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1OR?) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.